Ark Invest’s Cathie Wood Increases Baidu (BIDU) Stake Despite Trade Tensions

Photo of author

By Maxwell Reed

Amidst ongoing trade friction between Washington and Beijing, notable investment firm Ark Invest, led by Cathie Wood, has recently increased its exposure to a prominent Chinese technology company. This move signals a continued, albeit potentially counter-intuitive, interest in specific Chinese assets despite the challenging macroeconomic and political backdrop, characterized by significant reciprocal tariffs between the two nations.

The company receiving this increased attention is Baidu (BIDU), often recognized as China’s foremost search engine provider. Interestingly, Baidu is not only drawing attention from Ark Invest; it also represents the second-largest holding within Michael Burry’s Scion Asset Management portfolio, trailing only Alibaba (BABA).

Ark Invest’s Increased Stake in Baidu

Ark Invest acquired over 85,000 additional shares of Baidu, an investment valued at more than $7.5 million. Market observers speculate that this decision is largely driven by Baidu’s significant strides in the artificial intelligence sector. The company’s commitment to AI innovation was recently highlighted by the introduction of its advanced model, Ernie 4.5 Turbo.

Despite the broader concerns surrounding Chinese equities, Baidu’s US-listed shares have shown some resilience. Year-to-date, the stock has registered a gain of approximately 6%. However, it has also experienced considerable volatility recently, with its price oscillating between roughly $76 and $103 USD.

Other Recent Ark Invest Transactions

Beyond the Baidu acquisition, Ark Invest adjusted its portfolio through several other significant trades. These activities reflect the firm’s dynamic approach to managing its holdings in various sectors, particularly in biotechnology and financial technology.

Action Company (Ticker) Shares
Purchase Intellia Therapeutics (NTLA) 296,290
Purchase 10X Genomics (TXG) 150,986
Purchase Pacific Biosciences of California (PACB) 502,183
Sale Veracyte (VCYT) 48,678
Sale CRISPR Therapeutics (CRSP) 71,846
Sale Robinhood (HOOD) 121,999

These transactions indicate ongoing portfolio adjustments by Ark Invest, balancing positions across innovative technology and healthcare companies while navigating the complexities of the current global investment landscape.

Share